On February 18, these pharmaceutical companies issued announcements related to personnel changes, mergers and acquisitions, etc.

On February 18, a group of pharmaceutical companies in Shanghai and Shenzhen issued announcements, which were related to product progress, personnel changes, mergers and acquisitions, and other content
.
The following is a summary of the author's sorting out of some important announcements
.
【Product News】 Sinopharm Modern: Esomeprazole Sodium for Injection has obtained the drug registration certificate Sinopharm Modern announced, and Sinopharm Rongsheng, a wholly-owned subsidiary of the company, has received the "Esomeprazole for Injection" approved and issued by the State Food and Drug Administration.
Sodium" drug registration certificate
.
It is reported that esomeprazole sodium for injection can be used as an alternative therapy for gastroesophageal reflux disease when oral therapy is not applicable, to reduce the risk of rebleeding after endoscopic treatment of bleeding gastric and duodenal ulcers in adults, and to prevent severe The patient had a bleeding stress ulcer
.
Hisun Pharmaceutical: The application for the new specification of "Acarbose Tablets" has been approved.
Hisun Pharmaceutical announced that recently, the company has received the "Approval Notice of Drug Supplementary Application" for Acarbose Tablets approved and issued by the State Food and Drug Administration.

.
This product is based on the company's approved 50mg acarbose tablet, and applies for a new 100mg specification for the treatment of type 2 diabetes
.
[Personnel changes] Botuo Bio: Resignation of Supervisors and By-election of Non-employee Supervisors Botuo Bio's announcement shows that Mr.
Ye Chunsheng, a supervisor, applied to resign as a non-employee supervisor of the company due to work arrangements
.
After resigning as a non-employee supervisor, Mr.
Ye Chunsheng still holds other positions in the company
.
At the same time, on February 17, 2022, the company held the tenth meeting of the second board of supervisors.
The meeting reviewed and approved the "Proposal on the Resignation and By-election of Supervisors of the Company", and nominated Ms.
Zhao Danyun as a non-employee of the second board of supervisors of the company.
Candidates for representative supervisors, whose term of office starts from the date of deliberation and approval at the company's general meeting of shareholders and ends on the expiration date of the second session of the Supervisory Committee
.
[M&A and reorganization] Ruikang Pharmaceutical: It plans to acquire a 38.
4% stake in Tianjin Guohui Big Health Technology Co.
, Ltd.
for 230 million.
Ruikang Pharmaceutical issued an announcement on the proposed acquisition of equity and related transactions.
The company plans to report to the related party Yantai Huishuo Enterprise Management Partnership (Co.
, Ltd Partnership) to acquire its 38.
4% stake in Tianjin Guohuida Health Technology Co.
, Ltd.
at a consideration of 230 million yuan, accounting for 3.
08% of the company's net assets in the previous year
.
[Share repurchase] Haier Bio: Repurchase of 200,000 shares of the company Haier Bio released an announcement.
On February 17, 2022, the company repurchased 200,000 shares of the company for the first time through the Shanghai Stock Exchange trading system in a centralized bidding transaction, accounting for The proportion of the company's total share capital is 0.
06%, and the total amount of funds paid is 14.
7026 million yuan
.
[Funds to raise] Buchang Pharmaceutical: Increase of Idle Raised Funds by 200 Million Buchang Pharmaceutical announced that the company held the 14th meeting of the fourth board of directors on February 17, 2022, and the meeting reviewed and approved the "On Increasing Part of Idle Raised Funds The Proposal for Temporarily Supplementing Working Capital", it is proposed to increase the idle raised funds by 200 million yuan to temporarily supplement the working capital.
Special account for raised funds
.
[Other major events] Wandong Medical: Approval for Non-public Issuance of Shares Wandong Medical's announcement shows that the company has recently received the "Approval for the Approval of Beijing Wandong Medical Technology Co.
, Ltd.
's Non-public Issuance of Shares" issued by the China Securities Regulatory Commission.
The CSRC approves the company's non-public offering of no more than 162 million new shares, and if the total share capital changes due to circumstances such as conversion to share capital, the number of this offering may be adjusted accordingly
.
The issuance of shares shall be implemented in strict accordance with the application documents submitted by the company to the China Securities Regulatory Commission
.
This approval is valid for 12 months from the date of approval for issuance
.
Microchip Bio: The application for the issuance of convertible bonds to unspecified objects passed the microchip bio announcement that the Shanghai Stock Exchange Science and Technology Innovation Board Listing Committee held the ninth listing committee review meeting in 2022 on February 17, 2022.
The application for the issuance of convertible corporate bonds to unspecified objects was reviewed
.
The review results of the meeting showed that the company's application for this issuance met the issuance conditions, listing conditions and information disclosure requirements
.
Disclaimer: Under no circumstances does the information or opinions expressed in this article constitute investment advice to anyone
.